Evidence map›Paper›PMID 28603593›Full record

ArticleWorld journal of cardiology2017

Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patients.

Walter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Maria D Matoso, Patricia Sorroche, Juan A De Paula, Laura E Boero, Fernando Brites

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Combined ProbioticMolecules (Basel, Switzerland) · 2026
    Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Walter F TetzlaffWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Tomás MeroñoWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Martin MenafraWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Maximiliano MartinWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Eliana BottaWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Maria D MatosoWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Patricia SorrocheWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Juan A De PaulaWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Laura E BoeroWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Fernando BritesWalter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina.
Servicio Geológico Minero Argentino · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate novel risk factors and biomarkers of cardiovascular disease in celiac disease (CD) patients compared with healthy controls.

methodsTwenty adult patients with recent diagnosis of CD and 20 sex, age and body mass index-matched healthy controls were recruited during a period of 12 mo. Indicators of carbohydrate metabolism, hematological parameters and high sensitive C reactive protein were determined. Moreover, lipoprotein metabolism was also explored through evaluation of the lipid profile and the activity of cholesteryl ester transfer protein and lipoprotein associated phospholipase A2, which is also considered a specific marker of vascular inflammation. The protocol was approved by the Ethic Committee from School of Pharmacy and Biochemistry, University of Buenos Aires and from Buenos Aires Italian Hospital, Buenos Aires, Argentina.

resultsRegarding the indicators of insulin resistance, CD patients showed higher plasma insulin levels [7.2 (5.0-11.3) mU/L

conclusionThe presence and interaction of the detected alterations in patients with CD, would constitute a risk factor for the development of atherosclerotic cardiovascular disease.

Indexed as

Cardiovascular diseaseCeliac diseaseHigh density lipoprotein-cholesterolInflammationLipoproteins

Identifiers

PMID28603593
PMCPMC5442414
OpenAlexW2615380836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.